Evaluation of drug-drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and a clinical study
Description
Drug-drug interaction (DDI) potentials of ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, for drug transporters were evaluated by in vitro and clinical studies. The target drug transporters assessed were P-glycoprotein (P-gp)